Focused On-demand Library for N-alpha-acetyltransferase 25, NatB auxiliary subunit

Focused On-demand Libraries - Reaxense Collaboration

Explore the Potential with AI-Driven Innovation

The specialised, focused library is developed on demand with the most recent virtual screening and parameter assessment technology, guided by the Receptor.AI drug discovery platform. This approach exceeds the capabilities of traditional methods and offers compounds with higher activity, selectivity, and safety.

The compounds are cherry-picked from the vast virtual chemical space of over 60B molecules. The synthesis and delivery of compounds is facilitated by our partner Reaxense.

In the library, a selection of top modulators is provided, each marked with 38 ADME-Tox and 32 parameters related to physicochemical properties and drug-likeness. Also, every compound comes with its best docking poses, affinity scores, and activity scores, providing a comprehensive overview.

Our top-notch dedicated system is used to design specialised libraries.

Fig. 1. The sreening workflow of Receptor.AI

Our methodology leverages molecular simulations to examine a vast array of proteins, capturing their dynamics in both isolated forms and in complexes with other proteins. Through ensemble virtual screening, we thoroughly account for the protein's conformational mobility, identifying critical binding sites within functional regions and distant allosteric locations. This detailed exploration ensures that we comprehensively assess every possible mechanism of action, with the objective of identifying novel therapeutic targets and lead compounds that span a wide spectrum of biological functions.

Our library is unique due to several crucial aspects:

Receptor.AI compiles all relevant data on the target protein, such as past experimental results, literature findings, known ligands, and structural data, thereby enhancing the likelihood of focusing on the most significant compounds.
By utilizing advanced molecular simulations, the platform is adept at locating potential binding sites, rendering the compounds in the focused library well-suited for unearthing allosteric inhibitors and binders for hidden pockets.
The platform is supported by more than 50 highly specialized AI models, all of which have been rigorously tested and validated in diverse drug discovery and research programs. Its design emphasizes efficiency, reliability, and accuracy, crucial for producing focused libraries.
Receptor.AI extends beyond just creating focused libraries; it offers a complete spectrum of services and solutions during the preclinical drug discovery phase, with a success-dependent pricing strategy that reduces risk and fosters shared success in the project.

partner

Reaxense

upacc

Q14CX7

UPID:

NAA25_HUMAN

Alternative names:

Mitochondrial distribution and morphology protein 20; N-terminal acetyltransferase B complex subunit MDM20; N-terminal acetyltransferase B complex subunit NAA25; p120

Alternative UPACC:

Q14CX7; A0JLU7; Q6MZH1; Q7Z4N6; Q9H911

Background:

N-alpha-acetyltransferase 25, NatB auxiliary subunit, known by alternative names such as Mitochondrial distribution and morphology protein 20, N-terminal acetyltransferase B complex subunit MDM20, and p120, plays a crucial role in protein modification. It is a non-catalytic component of the NatB complex, responsible for the acetylation of N-terminal methionine residues in specific peptide sequences. This process is vital for the normal progression of the cell cycle, influencing cell growth and division.

Therapeutic significance:

Understanding the role of N-alpha-acetyltransferase 25 could open doors to potential therapeutic strategies. Its involvement in cell cycle progression highlights its potential as a target for developing treatments that could modulate cell growth, offering new avenues for cancer therapy and regenerative medicine.